XENOCOR Secures Investment from Growing Impact Ventures

Xenocor announces a series A-2 round investment by Growing Impact Ventures to enable increased production in response to growing market demand for the Xenoscope™, the first single–use, fog-free, HD laparoscopic imaging system.

Xenocor notes the Xenoscope provides both clinical and financial advantages that benefit surgeons, staff, healthcare facilities and most importantly, patients. It is well positioned to replace expensive, inflexible legacy technologies making laparoscopic surgery possible virtually anywhere.

“We strictly invest in companies that could have a dramatic impact on the health of human beings worldwide. These technologies must have the capacity to scale globally, as well as have the potential to drive positive societal transformation,” said John Evey, Managing Director of Growing Impact Ventures.  “The Xenoscope is such a product. Not only is it compact and portable, but it also delivers technological advances on several fronts, making it possible for high quality laparoscopic surgery to be done anywhere.  This means in a hospital, in an office, in cities and in the outback.”

The Xenoscope

The innovative technologies of the Xenoscope offer vastly improved image quality (HD and fog-free), eliminate cross-contamination, reduce technical complications and operation room downtimes. There are no large capital expenditures or expensive long-term maintenance contracts, making the Xenoscope accessible to markets of varying size.

“The advanced features of the Xenoscope have the potential to dramatically upend laparoscopic surgical processes and expenditures in countries which spend an inordinate amount of resources on healthcare. But equally important, these new capabilities can leap-frog over legacy technologies to quickly deliver a higher standard of care to those in countries which desperately need it,” said Evan Kelso, CEO of Xenocor. “Our focus now is to increase production and respond to the demand we are experiencing. This investment from Growing Impact Ventures facilitates a swift response.”

 

SourceXenocor
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy